Freeline Therapeutics IPO

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases.

Register for Details

For more details on financing and valuation for Freeline Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Freeline Therapeutics's ticker symbol?


What is Freeline Therapeutics's stock price?

0.4369 as of 3/24/23

Learn more about Freeline Therapeutics

Forge green plus iconForge green minus icon

What is Freeline Therapeutics funding to date?

Freeline Therapeutics has raised $205.53MM.
Forge green plus iconForge green minus icon

When was Freeline Therapeutics founded?

Freeline Therapeutics was founded in 2015.